1.46 USD
↘ 0.04 (2.67%)AT CLOSE (03:59 PM EDT)
Allogene Therapeutics, Inc. Common Stock
ALLONASDAQ • USD
1.48
↗ 0.02 (1.03%)
POST MARKET (AS OF 06:07 PM EDT)
Post Market
AS OF 06:07 PM EDT
1.48
↗ 0.02 (1.03%)
Market: OPEN
Allogene Therapeutics, Inc. Common Stock (ALLO) trades at $1.48 per share. Both sides of the analysis point lower: technicals flash "Strong Sell" and fundamentals confirm with a "Sell" reading. This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. On valuation, ALLO trades roughly in line with sector averages — neither particularly cheap nor expensive.
Technical & fundamental data as of Oct 6, 2026.
Open?$1.50
High?$1.50
Low?$1.43
Prev. Close?$1.50
Volume?4.7M
Avg. Volume?5.5M
VWAP?$1.46
Rel. Volume?0.85x
Bid / Ask
Bid?$1.25 × 100
Ask?$1.66 × 100
Spread?$0.41
Midpoint?$1.46
Valuation & Ratios
Market Cap?518.2M
Shares Out?345.5M
Float?274.9M
Float %?79.6%
P/E Ratio?N/A
P/B Ratio?1.19
EPS?-$0.48
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
Themes
Employees
152
Market Cap
518.2M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
Listed
2018-10-11
Address
210 EAST GRAND AVENUE
SOUTH SAN FRANCISCO, CA 94080
Phone: (650) 457-2700
SOUTH SAN FRANCISCO, CA 94080
Phone: (650) 457-2700
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-2/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?0
Momentum?65
Short Sent.?39
Piotroski F-Score?0/9Weak
Altman Z-Score?-3.01Distress
Confidence?54%Low
Short InterestSqueeze Risk
Short % of Float?21.68%Squeeze Risk
Short Interest?59.6M
Days to Cover?11.3
Free Float274.9M
Avg Daily Volume5.3M
Settlement Date2026-09-15
Financial Health
Current Ratio?10.72Strong
Quick Ratio?10.72Strong
Cash Ratio?1.22Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score67/100
P/E?N/A▾
P/B?1.19CHEAP▾
Peers100
S&P93
P/S?111.69HIGH▾
Peers100
S&P3
P/FCF?N/A▾
EV/EBITDA?-2.8CHEAP▾
S&P97
EV/Sales?103.36HIGH▾
Peers100
S&P3
Returns & Efficiency
ROE?-37.9%WEAK▾
S&P3
ROA?-30.1%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-102598000
Enterprise Value?$479.6M
Fundamentals ratios updated end of day